Ashland firm, WPI collaborate on stem-cell treatment
Courtesy of NuVascular Technologies
Ashland-based NuVascular Technologies Inc. said it has obtained exclusive licensing rights to commercialize a stem cell device that allows the heart to repair itself and improve its functions in as little as two to four weeks.
The device, known as the BioGenerator, is a minimally-invasive treatment for patients with coronary heart disease, according to NuVascular Technologies.
NuVascular is working with researchers at Worcester Polytechnic Institute (WPI) and BioSurfaces Inc., also of Ashland, to commercialize the technology. The BioGenerator employs BioSurfaces’ patented technology and stem cells derived from adult bone marrow at WPI. The device is a capsule that can be stitched into the heart-muscle wall or injected into the heart muscle through a catheter. The encased stem cells release proteins and growth factors that move through the device into the heart muscle, stimulating growth of tissue and repair of damage.
“We are confident that our devices can provide a minimally-invasive, highly effective treatment for heart disease that can actually reverse the damage rather than providing a temporary solution that often comes with complications,” said Matthew Phaneuf, founder and chief technology officer at NuVascular.
The company is also developing a biological pacemaker with researchers at Columbia University and Stony Brook University in New York.
WBJ Web Partners
Most Recent
Most Recent
0 Comments